Trial Profile
Effectiveness, safety and immunogenicity of CT-P13 in patients with Inflammatory-bowel-diseases who switched from originator infliximab: a real world study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Pharmacodynamics; Therapeutic Use
- 06 Dec 2018 New trial record